Polifeprosan 20
- Generic Name
- Polifeprosan 20
- Drug Type
- Small Molecule
- CAS Number
- 90409-78-2
- Unique Ingredient Identifier
- S40C40DA21
- Background
Polifeprosan 20 is under investigation in clinical trial NCT00003878 (Carmustine Implants in Treating Patients With Brain Metastases).
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Biological: lymphokine-activated killer cells
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Registration Number
- NCT00814593
- Locations
- ๐บ๐ธ
Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Barrett Cancer Center
- Registration Number
- NCT00003876
- Locations
- ๐บ๐ธ
Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004892
- Locations
- ๐บ๐ธ
Henry Ford Hospital, Detroit, Michigan, United States
๐บ๐ธH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
๐บ๐ธUniversity of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Duke University
- Registration Number
- NCT00003463
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธDuke Comprehensive Cancer Center, Durham, North Carolina, United States
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 3
- Registration Number
- NCT00045721
- Locations
- ๐บ๐ธ
Children's National Medical Center, Washington, District of Columbia, United States
๐บ๐ธDana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธChildren's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Carmustine Implants in Treating Patients With Brain Metastases
- Conditions
- Metastatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Registration Number
- NCT00003878
- Locations
- ๐บ๐ธ
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 68
- Registration Number
- NCT00003467
- Locations
- ๐บ๐ธ
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.